Blood and Marrow Transplant State of the Science Symposium

血液和骨髓移植科学现状研讨会

• 批准号: 7277455
• 负责人: JAMES L. M. FERRARA
• 金额: $ 2万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7277455
• 关键词: Agreement; Allogenic; American Society of Hematology; Blood; Cell Transplantation; Chairperson; Clinical; Clinical Research; Clinical Trials Network; Collection; Communities; Conduct Clinical Trials; Disease; Goals; Heart; Hematology; Hematopoietic; Institutes; Leadership; Lung; Malignant - descriptor; Marrow; Medical; Methods; Michigan; Morbidity - disease rate; National Cancer Institute; Non-Malignant; Numbers; Oral; Outcome; Patient Selection; Patients; Publishing; Purpose; Recommendation; Research; Risk; Science; Stem cells; Supportive care; Techniques; Time; Transplantation; United States; improved; mortality; novel; symposium

DESCRIPTION (provided by applicant): This proposal seeks support for the organization of a "State of the Science" Symposium in Hematopoietic Cell Transplantation (HCT) to be held in Ann Arbor, Michigan on June 26-27, 2007. Thousands of HCTs are performed to treat malignant and non-malignant diseases each year. Current estimates of annual numbers of HCTs are about 45,000 worldwide, with 15-20,000 annually in the United States. Reasons for increasing use include proven and potential efficacy in many diseases, better understanding of appropriate timing and patient selection, greater availability of donors and better techniques for determining HLA match, greater ease of stem cell collection, and improved supportive care. Despite these improvements, application of HCT is still limited by relatively high risks of morbidity and mortality and, in the case of allogeneic HCT, availability of suitable donors. In 2001, The National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute (NCI) jointly established a Blood and Marrow Transplant Clinical Trials Network (BMT CTN). The network's overarching goal is to conduct clinical trials that will definitively answer key questions in current HCT medical practice that can improve patient outcomes by assessing novel HCT methods and management strategies in a multi-center setting. The purpose of this symposium is to identify the most compelling clinical research opportunities that can be initiated in the next five years by the BMT CTN, and to disseminate its conclusions among the BMT and Hematology scientific communities. The recommendations of the first symposium, held in 2000, guided the scientific agenda of the BMT CTN during its first five years, and we expect the second symposium's recommendations to be equally important. The BMT CTN leadership has already formed twelve committees to evaluate recent advances in translational and clinical HCT research, and has received agreement from twelve distinguished leaders in the field to act as committee chairpersons. Importantly, we intend to publish the recommendations of the symposium and we plan oral presentations of the symposium's major findings at the 2007 ASH meeting and the 2008 Tandem meeting.

描述（由申请人提供）： 该提案寻求支持在2007年6月26日至27日在密歇根州安阿伯举行的造血细胞移植（HCT）中组织“科学状态”研讨会的组织。当前对HCT年度数量的估计在全球范围内约为45,000，在美国每年为15-20,000。增加使用的原因包括在许多疾病中进行验证和潜在功效，更好地理解适当的时间和患者的选择，更大的供体可用性以及确定HLA匹配的更好技术，更便捷的干细胞收集以及改善的支持性护理。尽管有这些改善，但HCT的应用仍受到发病和死亡率相对较高的风险，并且在同种异体HCT的情况下，适用于合适的供体。 2001年，国家心脏，肺和血液研究所（NHLBI）和国家癌症研究所（NCI）共同建立了血液和骨髓移植临床试验网络（BMT CTN）。该网络的总体目标是进行临床试验，这些试验将在当前的HCT医学实践中明确回答关键问题，该问题可以通过评估新型的HCT方法和管理策略在多中心环境中改善患者的结果。 该研讨会的目的是确定BMT CTN在未来五年内可以引发的最引人注目的临床研究机会，并在BMT和血液学科学社区中分发其结论。这 2000年举行的第一届研讨会的建议指导了BMT CTN在头五年中的科学议程，我们预计第二次研讨会的建议同样重要。 BMT CTN领导层已经成立了十二个委员会，以评估转化和临床HCT研究的最新进展，并获得了该领域十二位杰出领导人的协议，担任委员会主席。 重要的是，我们打算发表研讨会的建议，并计划在2007年ASH会议和2008年串联会议上进行研讨会的主要调查结果。